PubMed Health⌕ Search

Biomedical subjects

R Hecker

Publications and source records attributed to R Hecker.

At least 55 records · Page 3Linked to original sources
PubMed1982

Ultrastructure and electron-probe x-ray analysis of the pigment in melanosis duodeni.

A patient with peptic ulceration developed melanosis duodeni, which was studied by light microscopy, histochemistry, electron microscopy and electron-probe x-ray analysis. Our studies show that the pigment in melanosis duodeni resides in the lysosomes of macrophages in the lamina propria. The pigment is not melanin or a melanin-like compound as has been claimed by previous workers. On the basis of electron-probe x-ray analytical findings we have concluded that the pigment is essentially FeS. On the basis of the history of this patient and cases reported in the literature we think that the Fe in this pigment is derived from haemorrhage in the gastrointestinal tract. We also found small amounts of Ca, K, Al, Mg, Si, and Ag. It would appear that Al, Mg and Si were probably derived from the biological milieu and/or other drugs and/or food and/or specimen contamination.

Cytoplasmic Granules↗
PubMed1981

Medical manpower in South Australia with special reference to general practitioners.

A survey of general-practitioner and total medical manpower in South Australia has been made through the AMA local associations. This reveals that a sizeable increase in medical manpower, particularly for general practitioners, is likely in the coming decade. Immediate attention is warranted to find solutions to problems which can be expected to arise from a possible oversupply of doctors. The solutions will need to be acceptable to universities, governments, the AMA and the Australian people.

Australia↗
PubMed1980

Long-term treatment of duodenal ulcer with cimetidine. Intermittent or continuous therapy?

Forty-eight patients with chronic duodenal ulcers which were healed with cimetidine were allocated at random into two equal groups to assess different ways of using cimetidine during one year of treatment. Twenty-four patients received intermittent six-week courses of cimetidine for each relapse, and 24 patients were treated with maintenance administration of cimetidine (400 mg twice a day) continuously. Only one patient in the group receiving continuous therapy suffered clinical recurrence, but asymptomatic ulceration was found in four others. The group of patients who were receiving intermittent therapy suffered a total of 36 clinical recurrences. Three of these patients required prolonged treatment to heal their ulcers, and seven developed asymptomatic ulcer. The number of relapses varied from none to five. No way of predicting the individual prognosis was found. Intermittent treatment was an acceptable alternative in approximately half of the patients treated in this way, and was a failure in one-quarter of the group.

Adult↗
PubMed1980

Double-blind trial of trimipramine in the treatment of duodenal ulcer.

Twenty-three patients with chronic duodenal ulcer were allocated randomly to receive either trimipramine 25 mg or placebo, as a single night-time dose, for six weeks. Ulcer healing was determined by endoscopy. The ulcer healed in two of 10 patients receiving trimipramine and in seven of 13 patients receiving placebo. Trimipramine in this dosage does not assist ulcer healing.

Clinical Trials as Topic↗
PubMed1980

Gastroenterology.

Explore the source record for details and available documents.

Digestive System↗
PubMed1980

Carcinoma of the stomach--prognostic factors and current treatment.

Two-hundred-and-six cases of gastric carcinoma were analysed for survival on the basis of their clinical, endoscopic and operative findings. An attempt has been made to identify prognostic factors and the role of edoscopy. It is concluded that too much radical surgery is being performed in patients who can be recognised preoperatively as having obviously advanced disease.

Aged↗
PubMed1979

Prevention of duodenal ulcer relapse by cimetidine: a one-year double-blind trial.

Fifty-one patients with duodenal ulcer which was healed by a six-week course of cimetidine completed a one-year double-blind study to compare the effects of cimetidine and placebo on the prevention of ulcer relapse. Patients were allocated at random to receive either 400 mg of cimetidine twice daily or placebo. Ulcer relapse was assessed by regular clinical follow up and endoscopy. A total of six of the 24 cimetidine-treated patients (25%) suffered a relapse compared to 25 of the 27 of placebo-treated patients (92.6%). Out of this total number of relapses, asymptomatic relapse with ulceration discovered by routine endoscopy at six months or one year, occurred in three patients receiving cimetidine and eight patients receiving placebo. Cimetidine prevents recurrence in patients with duodenal ulcer disease.

Adult↗
PubMed1978

Cimetidine treatment of duodenal ulceration: short term clinical trial and maintenance study.

Eighty-five patients with endospcopically confirmed duodenal or pyloric canal ulcers entered a double blind trial with 1200 mg of cimetidine per day or placebo for 6 weeks. Eighty-four per cent of patients treated with cimetidine and 38 percent of those receiving placebo healed their ulcers (P less than 0.001). Measurement of basal acid output and maximal acid output before and after treatment showed no significant change but patients who failed to heal their ulcers had a higher basal acid output and maximal acid output than those who healed. Patients who smoked or drank alcohol had the same healing rate as abstainers. Sity-seven patients with duodenal ulceration healed by a 6-week course of cimetidine were randomly allocated to 400 mg of cimetidine twice daily or placebo in the maintenance trial. Actuarial analysis of the number of relapses in each group demonstrates that cimetidine is highly effective in preventing relapse.

Adult↗
PubMed1977

Cimetidine in the treatment of duodenal ulcer.

In a double-blind trial performed in two centres, 67 outpatients with endoscopically confirmed duodenal (55) or pyloric canal (12) ulcers received cimetidine (34 patients) or placebo (33 patients) for six weeks. At 6 weeks complete healing of ulcers was significantly increased in patients receiving cimetidine (82%) compared with those receiving placebo (39%) (chi2=11-27; P less than 0-0008). Patients receiving cimetidine had significantly less daytime pain and required less antacid than those receiving placebo. Gastric acid secretion measured one week after cessation of treatment demonstrated that there was no rebound hypersecretion of acid in patients who had received cimetidine. The pretrial basal acid output of those patients whose ulcers failed to heal during cimetidine therapy was significantly greater than that of those whose ulcers healed during treatment with the drug (P less than 0-001). No side effects were encountered.

Adult↗